1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. (23rd October 2018) - Diab, A; Haymaker, C; Bernatchez, C; Andtbacka, R H I; Shaheen, M; Johnson, D; Markowitz, J; Puzanov, I; Murthy, R; Johnson, D H; James, M; Chunduru, S; et al.